Starling Oncology, Inc. Stock Issued During Period, Value, Restricted Stock Award, Gross
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Starling Oncology, Inc. stock issued during period, value, restricted stock award, gross for the quarter ending 2023-09-30 was $1.00K.
- Starling Oncology, Inc. stock issued during period, value, restricted stock award, gross for the quarter ending 2022-03-31 was $0.00.
- Starling Oncology, Inc. stock issued during period, value, restricted stock award, gross for fiscal 2025 was $0.00.
- Starling Oncology, Inc. stock issued during period, value, restricted stock award, gross for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Starling Oncology, Inc. stock issued during period, value, restricted stock award, gross for fiscal 2023 was $1.00K.
| Period end | Stock Issued During Period, Value, Restricted Stock Award, Gross 3 month | Stock Issued During Period, Value, Restricted Stock Award, Gross 12 month |
|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-12 | |
| 2024-12-31 | $0.00 10-K · filed 2026-03-12 | |
| 2023-12-31 | $1.00K 10-K · filed 2025-03-26 | |
| 2023-09-30 | $1.00K 10-Q · filed 2024-11-13 | |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-10 |